Prognosis of Long‐Term Continuous Renal Replacement Therapy and the Impact of Combined Continuous Intravenous Sodium Infusion Therapy Authors: Akinori Yamaguchi, Atsuyoshi Mita, Kosuke Sonoda, Makoto Harada, Koji Hashimoto, Hiroshi Imamura, Yuji Kamijo Published: 2026 ABSTRACT ABSTRACTIntroductionPatients requiring long‐term continuous renal replacement therapy (CRRT) generally have poor prognoses. This study evaluated whether adding continuous intravenous sodium infusion (cIVNa) is associated with improved hemodynamics and outcomes in patients undergoing long‐term CRRT for ≥ 7 days.MethodsThis secondary analysis included 46 patients with acute kidney injury who required ≥ 7 days of CRRT from a previously published cohort. Patients received either conventional CRRT (n = 24) or CRRT plus cIVNa (n = 22). Hemodynamic parameters, fluid balance, laboratory findings, and clinical outcomes were compared.ResultscIVNa group exhibited more stable hemodynamics, higher urine output, and a more favorable fluid balance. Rates of 90‐day survival without renal replacement therapy (RRT) (42.9% vs. 12.5%, p < 0.05), survival to ICU discharge (68.2% vs. 29.2%, p < 0.05), and CRRT/RRT withdrawal were significantly higher among patients receiving cIVNa than among those receiving conventional CRRT.ConclusioncIVNa may support hemodynamic stability and improve RRT withdrawal and survival outcomes in patients requiring long‐term CRRT. Introduction Acute kidney injury (AKI) requiring renal replacement therapy (RRT) continues to be associated with substantial morbidity and mortality despite significant advances in critical care. Previous multicenter randomized controlled trials (RCTs) have demonstrated that mortality among patients with AKI requiring RRT remains high, ranging from 44% to 69% [1, 2, 3, 4, 5, 6, 7, 8]. Continuous renal replacement therapy (CRRT) is frequently used in hemodynamically unstable patients; however, fluctuations in blood pressure during treatment remain a major concern [9] and may compromise kidney recovery or exacerbate other organ dysfunctions. Several strategies—including low‐temperature dialysate, bicarbonate‐buffered solutions, and high‐sodium dialysate—have been implemented in intermittent hemodialysis (IHD) and sustained low‐efficiency dialysis (SLED) to mitigate intradialytic hypotension and facilitate fluid removal in critically ill patients with AKI [9, 10, 11, 12]. High‐sodium dialysate, defined as a sodium concentration higher than that used in conventional chronic hemodialysis (i.e., 138–140 mEq/L), provides osmotic support for intravascular volume, enhances plasma refilling [9, 10, 13], suppresses rapid decreases in extracellular fluid volume [10, 13], and helps maintain hemodynamic stability during RRT. Dialysate sodium concentrations exceeding 145 mEq/L are generally recommended for hemodynamic support during IHD or SLED in critically ill patients [9, 10, 14, 15]. Building on this physiological principle, we previously examined a multimodal strategy combining CRRT with continuous intravenous sodium infusion (cIVNa) as a practical alternative to high‐sodium dialysate. That study indicated that sodium supplementation during CRRT was associated with improved hemodynamic stability, urine output, kidney recovery, and survival compared with conventional CRRT [16]. Patients who remain dependent on CRRT for 1 week or longer represent a population with particularly poor prognoses. However, evidence regarding the potential benefits of sodium‐supplemented CRRT in long‐term CRRT recipients remains limited. Therefore, in this secondary analysis using our previously reported dataset, we specifically evaluated patients who underwent CRRT for ≥ 7 days to determine whether the addition of cIVNa affects hemodynamics, fluid balance, kidney recovery, and survival. Materials and Methods Study Design This study was a secondary analysis of a previously published single‐center cohort of adult patients with AKI who received CRRT in the intensive care unit (ICU) of Shinshu University Hospital between January 2015 and December 2022 [16]. The original dataset comprised 194 patients, of whom 92 met the full eligibility criteria after excluding those with chronic kidney disease stage G5 before admission, those undergoing dialysis prior to ICU admission, patients with nonprerenal etiologies of AKI, and those requiring specialized therapies such as immunosuppression (for autoimmune diseases or graft‐versus‐host disease), chemotherapy (for tumor lysis syndrome), plasma exchange, or blood and organ transplantation (hepatic failure and liver transplantation‐related events) (Figure 1). Patients demonstrating sufficient plasma refilling at CRRT initiation (defined as systolic blood pressure > 140 mmHg without vasopressors or urine output > 100 mL/h) were also excluded. Of the 92 eligible individuals, 13 patients died and 33 patients discontinued CRRT within 6 days; the remaining 46 patients who required CRRT for at least 7 days were included in this analysis. Based on the treatment received, patients were classified into either the conventional CRRT group (control group; n = 24) or the CRRT plus cIVNa group (intervention group; n = 22). Clinical parameters were statistically compared between the two groups. Because cIVNa was introduced at our institution in 2019, all patients in the intervention group were treated during the later years of the study period. Study flowchart. This study represents a secondary analysis of a previously published single‐center cohort of adults with AKI who received CRRT between January 2015 and December 2022. To evaluate the therapeutic effects of cIVNa in patients with prerenal AKI and impaired plasma refilling, individuals meeting exclusion criteria were omitted. Patients who died or discontinued CRRT within 6 days were also excluded. Ultimately, 46 patients who required CRRT for at least 7 days were included. Based on the actual treatment administered, patients were classified into the conventional CRRT group (control; n = 24) or the CRRT + cIVNa group (intervention; n = 22). Clinical parameters were compared statistically between groups. cIVNa, continuous intravenous sodium infusion; CRRT, continuous renal replacement therapy; eGFR, estimated glomerular filtration rate; IHD, intermittent hemodialysis. Administration of cIVNa The CRRT system used in our ICU does not permit in‐line modification of the dialysate sodium concentration. Therefore, sodium supplementation was administered intravenously as a practical alternative to high‐sodium dialysate. The details of this adjustment method were described in our previous study [16], and the key points are illustrated in Figure S1. A concentrated sodium chloride solution (50 mEq/20 mL) was continuously infused, starting at approximately 5 mEq/h. The infusion rate was titrated in small increments according to hemodynamic stability, ultrafiltration requirements, and the overall assessment of intravascular volume by critical care nephrologists. Because ultrafiltration removes sodium at concentrations similar to those of plasma (approximately 140 mEq/L), considerable sodium loss may occur during CRRT. Additional sodium was infused to compensate for this loss and to simulate normal kidney autoregulation. Sodium bicarbonate was substituted for sodium chloride when chloride‐associated acidosis was a concern. In patients receiving enteral nutrition or those without nutritional supplementation, the standard cIVNa dose was maintained at 2.5–10 mEq/h (60–240 mEq/day). However, patients receiving total parenteral nutrition (TPN) often require increased removal of mechanical fluids via ultrafiltration. To compensate for the loss of sodium during ultrafiltration, the administered cIVNa dose was further increased. To avoid increasing the frequency of syringe changes, a portion of cIVNa was occasionally administered as a sodium‐mixed injection during TPN. Clinical Data Collection Methods Clinical data were obtained from electronic medical records and included demographic characteristics (sex and age), systolic blood pressure, and serum levels of creatinine, urea nitrogen, and sodium at CRRT initiation, as well as any decrease in urine output (< 100 mL) within the 6 h preceding treatment. Underlying disease categories (postoperative, cardiac, or infectious) and surgical variables—including cardiopulmonary bypass use, surgical type (cardiac, vascular, digestive, or other), infectious complications, and urgency—were also documented. Illness severity was assessed using the Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores at ICU admission and at CRRT initiation. The use of vasopressors, mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and ventricular assist devices (VAD) was recorded, along with the total duration of CRRT in days. The amount of cIVNa administered over 24 h, from 6:00 a.m. each Day to 6:00 a.m. the following day on Days 1, 4, and 7, was measured. These data also included the amount of sodium added to the TPN. Outcome measures included survival at 28, 60, and 90 days; 90‐day survival without RRT or CRRT; dependence on RRT, CRRT, or IHD among 90‐day survivors; survival to ICU and hospital discharge; CRRT withdrawal (defined as being free from CRRT for ≥ 7 days); RRT withdrawal (defined as being free from RRT for ≥ 7 days); and reinitiation of CRRT or RRT after withdrawal. Adverse events assessed within 14 days of CRRT initiation included hypotension requiring rapid fluid resuscitation (using crystalloid solutions, blood transfusions, or albumin preparations) or vasopressor escalation, hypertension requiring antihypertensive therapy, arrhythmias requiring antiarrhythmic drugs and/or electrical defibrillation, bleeding events, and new‐onset hypernatremia (serum sodium ≥ 150 mEq/L). “Hypotension requiring intervention” was defined as an increase in rapid fluid resuscitation and/or vasopressor escalation due to hypotension. Hypernatremia occurring at or within 14 days after CRRT withdrawal was also recorded. During the first week of therapy, systolic blood pressure, urine output, ultrafiltration volume, total infused fluid, total excreted fluid (including urine, drainage, and bleeding), and net fluid balance were recorded daily. Because accurate calculation of body fluid volume was not feasible in patients transferred from other wards or with missing data after ICU discharge, fluid management data were collected only from the day following CRRT initiation in the ICU. These data were recorded from 6:00 a.m. on 1 day to 6:00 a.m. the next, excluding days of death or discharge. Serum sodium, blood glucose, blood urea nitrogen, and calculated osmolar parameters were also assessed. Osmolality was calculated as (2 × Na) + (blood glucose ÷ 18) + (urea nitrogen ÷ 2.8), and tonicity as (2 × Na) + (blood glucose ÷ 18). Serum sodium levels were recorded throughout the ICU stay, including data from the day of death or discharge. Statistical Analysis Categorical variables were expressed as numbers (percentages) and compared using Fisher's exact test. Continuous variables with normal and nonnormal distributions were expressed as mean ± standard deviation and median (interquartile range), respectively. Continuous data were analyzed using either Student's t‐test (for normally distributed variables) or the Mann–Whitney U test (for nonnormally distributed variables). Daily data on systolic blood pressure, fluid management, and osmolality‐related parameters were expressed as mean ± standard error (SE) and compared using the Mann–Whitney U test as exploratory at first. Subsequently, a mixed‐effects model (MEMs) analysis was performed on representative daily parameters. A two‐sided p < 0.05 was considered statistically significant. All statistical analyses, other than MEMs, were performed using EZR on R Commander (Saitama Medical Center, Jichi Medical University, Saitama, Japan) [17]. The MEMs analysis was performed using R v.4.3.2 (R Foundation for Statistical Computing, Vienna, Austria). The overall intervention‐by‐time interaction was assessed using the joint Wald test for all spline interaction terms. Effect estimates are reported with their corresponding SE. Analyses were performed using the lme4 and lmerTest R packages for model fitting and significance testing, and splines for spline basis functions. Results Baseline Characteristics of Patients Among the 46 long‐term CRRT recipients included in this analysis, 24 patients received conventional CRRT and 22 received CRRT combined with cIVNa (Table 1). Baseline demographic and clinical characteristics were generally similar between the two groups. Severity scores at ICU admission and CRRT initiation did not differ significantly. Serum sodium levels at CRRT initiation were significantly higher in the intervention group. Most patients were in the postoperative cardiac or vascular category, whereas relatively few had infections. In the intervention group, a significantly higher number of patients underwent cardiopulmonary bypass. Although not statistically significant, a greater proportion of patients in the intervention group underwent emergency surgery. There were no significant differences between groups in systolic blood pressure, serum creatinine, or blood urea nitrogen levels at CRRT initiation; in the percentage of patients with decreased urine output (< 100 mL within the 6 h before CRRT initiation); or in illness severity scores, including the APACHE II and SOFA scores. The rates of vasopressor use, mechanical ventilation, and ECMO/VAD support were comparable. The median duration of CRRT was also similar between groups. TABLE 1Baseline characteristics of patients.VariableControl (CRRT)Intervention (CRRT + cIVNa) p Cases, n 2422Gender (men), n (%)17 (70.8%)18 (81.8%)0.50Age (years)72.5 (65.7–78.0)70.5 (57.0–75.3)0.37Systolic blood pressure (mmHg)95.5 (82.5–108.5)101.5 (84.3–115.0)0.41Serum creatinine (mg/dL)3.69 ± 1.33.41 ± 1.30.48Serum urea nitrogen (mg/dL)60.7 (47.1–91.8)68.1 (41.2–109.5)0.85Decreased urine output < 100 mL within 6 h before CRRT initiation, n (%)10/22 (45.5%)12 (54.5%)0.76Serum sodium (mEq/L)140.8 ± 6.9146.3 ± 7.90.02*Serum sodium ≥ 150 mEq/L, n (%)2 (8.3%)7 (31.8%)0.07Postoperative status, n (%)20 (83.3%)19 (86.4%)1.00Heart disease, n (%)14 (58.3%)15 (68.2%)0.55Infection, n (%)6 (25.0%)8 (36.4%)0.53Cardiopulmonary bypass use, n (%)10/20 (50.0%)17/19 (89.5%)0.01*Cardiac surgery, n (%)6/20 (30.0%)11/19 (57.9%)0.11Vascular surgery, n (%)12/20 (60.0%)14/19 (73.7%)0.50Digestive surgery, n (%)3/20 (15.0%)1/19 (5.3%)0.61Other organ surgery, n (%)2/20 (10.0%)1/19 (5.3%)1.00Surgery with infection, n (%)2/20 (10.0%)1/19 (5.3%)1.00Emergency surgery, n (%)8/20 (40.0%)14/19 (73.7%)0.053Scheduled surgery, n (%)12/20 (60.0%)5/19 (26.3%)0.053APACHE II score at ICU admission28.8 ± 6.927.4 ± 6.20.46SOFA score at ICU admission12.0 ± 4.613.2 ± 3.20.31SOFA score at CRRT initiation13.8 ± 4.313.3 ± 3.60.59Vasopressor use, n (%)18 (75.0%)17 (77.3%)1.00Ventilator use, n (%)19 (79.2%)18 (81.8%)1.00ECMO/VAD at CRRT initiation, n (%)5 (20.8%)4 (18.2%)1.00ECMO/VAD during CRRT, n (%)7 (29.2%)5 (22.7%)0.74CRRT duration (days)20.0 (9.0–61.3)15.5 (11.0–22.8)0.49cIVNa on Day 1 [mEq/day]—65.6 (0–122.5)—cIVNa on Day 4 [mEq/day]—167.2 ± 108.2—cIVNa on Day 7 [mEq/day]—173.0 ± 138.5— Note: Categorical variables are presented as numbers (percentages) and were compared using Fisher's exact test. Normally and nonnormally distributed data are expressed as mean ± standard deviation and median (interquartile range), respectively. Normally distributed variables were compared using the Student's t‐test; nonnormally distributed variables were compared using the Mann–Whitney U test. cIVNa, continuous intravenous sodium infusion; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; VAD, ventricular assist device. Baseline characteristics of patients. Note: Categorical variables are presented as numbers (percentages) and were compared using Fisher's exact test. Normally and nonnormally distributed data are expressed as mean ± standard deviation and median (interquartile range), respectively. Normally distributed variables were compared using the Student's t‐test; nonnormally distributed variables were compared using the Mann–Whitney U test. cIVNa, continuous intravenous sodium infusion; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; VAD, ventricular assist device. In the intervention group, the amount of IVNa, including sodium combined with TPN, was 65.6 (0–122.5) mEq/day on Day 1, 167.2 ± 108.2 mEq/day on Day 4, and 173.0 ± 138.5 mEq/day on Day 7. On Day 1, 10 of the 22 patients had not yet received cIVNa, and in the 12 patients who had received cIVNa, the dose was 122 (96.3–203.2) mEq/day. Main Outcome Outcomes are summarized in Table 2. Patients in the control group who required long‐term CRRT exhibited poor prognoses: 90‐day overall survival was 37.5%, 90‐day survival without RRT was 12.5%, and survival to ICU discharge was 29.2%. The rate of survival to hospital discharge was also 29.2%. The CRRT withdrawal rate was 33.3%, and the RRT withdrawal rate was 25.0%. Among the nine 90‐day survivors in the control group, only three patients were independent of RRT, while the remaining six patients continued to receive either CRRT (three patients) or IHD (three patients). TABLE 2Main outcomes.VariableControl (CRRT)Intervention (CRRT + cIVNa) p Cases, n 242228‐day survival, n (%)16 (66.7%)20 (90.9%)0.0760‐day survival, n (%)12 (50.0%)13/21 (61.9%)0.5590‐day survival, n (%)9 (37.5%)12/21 (57.1%)0.2390‐day survival without CRRT, n (%)6 (25.0%)11/21 (52.4%)0.0790‐day survival without RRT, n (%)3 (12.5%)9/21 (42.9%)0.04*RRT dependence among 90‐day survivors, n (%)6/9 (66.7%)3/12 (25.0%)0.09CRRT dependence among 90‐day survivors, n (%)3/9 (33.3%)1/12 (8.3%)0.27IHD dependence among 90‐day survivors, n (%)3/9 (33.3%)2/12 (16.7%)0.61Survival to ICU discharge, n (%)7 (29.2%)15 (68.2%)0.02*Survival to hospital discharge, n (%)7 (29.2%)13 (59.1%)0.07RRT modality: CRRT only, n (%)19 (79.2%)12 (54.5%)0.12RRT modality: CRRT + IHD, n (%)5 (20.8%)10 (45.5%)0.12CRRT withdrawal, n (%)8 (33.3%)18 (81.8%)0.001**CRRT reinitiation after withdrawal, n (%)1/8 (12.5%)4/18 (22.2%)1.00RRT withdrawal, n (%)6 (25.0%)14 (63.6%)0.02*RRT reinitiation after withdrawal, n (%)1/6 (16.7%)3/14 (21.4%)1.00 Note: Data are presented as numbers (percentages) and were compared using Fisher's exact test.*p < 0.05, **p < 0.01, compared between the intervention and control groups.“CRRT withdrawal” was defined as surviving > 7 days without CRRT after discontinuation.“RRT withdrawal” was defined as surviving > 7 days without RRT after discontinuation.Abbreviations: cIVNa, continuous intravenous sodium infusion; CRRT, continuous renal replacement therapy; ICU, intensive care unit; IHD, intermittent hemodialysis; RRT, renal replacement therapy. Main outcomes. Note: Data are presented as numbers (percentages) and were compared using Fisher's exact test. *p < 0.05, **p < 0.01, compared between the intervention and control groups. “CRRT withdrawal” was defined as surviving > 7 days without CRRT after discontinuation. “RRT withdrawal” was defined as surviving > 7 days without RRT after discontinuation. Abbreviations: cIVNa, continuous intravenous sodium infusion; CRRT, continuous renal replacement therapy; ICU, intensive care unit; IHD, intermittent hemodialysis; RRT, renal replacement therapy. In contrast, the intervention group demonstrated improved outcomes. 90‐day survival without RRT was significantly higher (42.9% vs. 12.5%, p < 0.05) (Figure 2A). Survival to ICU discharge (68.2% vs. 29.2%, p < 0.05) (Figure 2B), CRRT withdrawal (81.8% vs. 33.3%, p < 0.01) (Figure 2C), and RRT withdrawal (63.6% vs. 25.0%, p < 0.05) (Figure 2D) were all significantly higher in the cIVNa group. Although overall survival at 28, 60, and 90 days and the rate of transition from CRRT to IHD were numerically greater, and RRT, CRRT, and IHD dependence rates among 90‐day survivors were lower, these differences did not reach statistical significance—likely due to the limited sample size. CRRT and RRT reinitiation rates after withdrawal were comparable between groups. Outcomes and complications. Outcomes and complications showing statistically significant differences between the control and intervention groups are presented. (A) 90‐Day survival without RRT; (B) survival to ICU discharge; (C) CRRT withdrawal; (D) RRT withdrawal; (E) hypotension requiring intervention; and (F) Hypotension requiring vasopressor escalation. Data are expressed as numbers (percentages) and were compared using Fisher's exact test. “CRRT withdrawal” was defined as being free from CRRT for ≥ 7 days. “RRT withdrawal” was defined as being free from RRT for ≥ 7 days. “Hypotension requiring intervention” was defined as hypotension necessitating rapid fluid resuscitation and/or vasopressor escalation. Abbreviations: cIVNa, continuous intravenous sodium infusion; CRRT, continuous renal replacement therapy; ICU, intensive care unit; RRT, renal replacement therapy. Complications Among the complications that occurred within 14 days of CRRT initiation, hypotension requiring intervention or vasopressor escalation occurred significantly less frequently in the intervention group (36.4% vs. 75.0%, p < 0.05; and 27.3% vs. 62.5%, p < 0.05, respectively) (Figure 2E,F and Table 3). The incidences of hypotension requiring rapid fluid resuscitation, hypertension requiring antihypertensive therapy, arrhythmias, and bleeding events were comparable between groups. The rate of new‐onset hypernatremia (serum sodium ≥ 150 mEq/L) within 14 days after CRRT initiation and within 14 days after CRRT withdrawal was higher in the intervention group, although the differences were not statistically significant (18.8% vs. 0%, p = 0.07; 50.0% vs. 12.5%, p = 0.18, respectively). Hypernatremia (serum sodium ≥ 150 mEq/L) at CRRT withdrawal was not observed in the control group but occurred more frequently in the intervention group (11.1%), though this difference was also not statistically significant. TABLE 3Complications.Control (CRRT)Intervention (CRRT + cIVNa) p CRRT‐related complications within 14 days after CRRT initiationCases, n 2422Hypotension requiring intervention, n (%)18 (75.0%)8 (36.4%)0.02*Hypotension requiring rapid fluid resuscitation, n (%)11 (45.8%)4 (18.2%)0.06Hypotension requiring vasopressor escalation, n (%)15 (62.5%)6 (27.3%)0.02*Hypertension requiring antihypertensive therapy, n (%)7 (29.2%)9 (40.9%)0.54Arrhythmia requiring antiarrhythmic therapy and/or electrical defibrillation, n (%)10 (41.7%)6 (27.3%)0.36Bleeding events, n (%)1 (4.2%)0 (0.0%)1.00New‐onset hypernatremia (Na ≥ 150 mEq/L), n (%)0/22 (0.0%)3/16 (18.8%)0.07Complications at or after CRRT withdrawalPatients achieving CRRT withdrawal, n 818—Hypernatremia (Na ≥ 150 mEq/L) at CRRT withdrawal, n (%)0 (0.0%)2 (11.1%)1.00New‐onset hypernatremia (Na ≥ 150 mEq/L) within 14 days after CRRT withdrawal, n (%)1 (12.5%)8/16 (50.0%)0.18 Note: Data are presented as numbers (percentages) and were compared using Fisher's exact test.*p < 0.05, compared between the intervention and control groups.“CRRT withdrawal” was defined as surviving > 7 days without CRRT after discontinuation.“RRT withdrawal” was defined as surviving > 7 days without RRT after discontinuation.Abbreviations: cIVNa, continuous intravenous sodium infusion; CRRT, continuous renal replacement therapy; ICU, intensive care unit; IHD, intermittent hemodialysis; RRT, renal replacement therapy. Complications. Note: Data are presented as numbers (percentages) and were compared using Fisher's exact test. *p < 0.05, compared between the intervention and control groups. “CRRT withdrawal” was defined as surviving > 7 days without CRRT after discontinuation. “RRT withdrawal” was defined as surviving > 7 days without RRT after discontinuation. Abbreviations: cIVNa, continuous intravenous sodium infusion; CRRT, continuous renal replacement therapy; ICU, intensive care unit; IHD, intermittent hemodialysis; RRT, renal replacement therapy. Hemodynamic and Fluid Management Systolic blood pressure increased within the first day in the intervention group and remained consistently higher throughout the first week, with significant differences observed on Days 1 and 3 (111.7 ± 3.6 mmHg vs. 105.8 ± 4.8 mmHg, p < 0.05; 120.0 ± 4.5 mmHg vs. 104.3 ± 4.5 mmHg, p < 0.01) (Figure 3A and Table S1). Urine output remained low in the control group but increased progressively in the intervention group, exceeding 1300 mL/day from Day 2 onward. On Days 3–5, urine output was significantly higher in the intervention group than in the control group (p < 0.05 for all) (Figure 3B). Mechanical fluid removal requirements were significantly lower in the intervention group on Days 1 and 2 (p < 0.05). The total volume of fluid administration did not differ between groups. Total daily fluid excretion in the intervention group was maintained at approximately 2500 mL from Day 2 onward and was significantly greater than that of the control group on Days 5–7, resulting in an increasingly negative fluid balance. In contrast, the control group remained fluid‐positive throughout this period. Changes in systolic blood pressure, urine output, serum sodium level, and osmolality. (A) Systolic blood pressure; (B) urine output; (C) serum sodium level; and (D) Change in osmolality from baseline. Systolic blood pressure was recorded every 24 h following CRRT initiation. Urine output was collected from 6 a.m. to 6 a.m. the following day, excluding data from the day of death or discharge. Osmolality was calculated as (2 × Na) + (glucose/18) + (blood urea nitrogen/2.8), and changes from baseline were plotted. p‐Values are indicated when significant differences were observed between the control and intervention groups. Abbreviation: CRRT, continuous renal replacement therapy. Serum Sodium Level, Osmolality, and Tonicity Serum sodium levels declined to approximately 137 mEq/L in the control group but remained consistently and significantly higher in the intervention group (approximately 144 mEq/L) (Figure 3C and Table S1). In the intervention group, blood urea nitrogen levels were significantly higher than those in the control group from Day 3 onward. Blood glucose levels did not differ significantly between the intervention and control groups throughout the first week. Osmolality was significantly higher in the intervention group from Day 1 onward, and tonicity was significantly higher from Day 0 onward. Decreases in osmolality and tonicity from baseline were more pronounced in the control group, whereas these changes occurred more gradually in the intervention group (Figure 3D). Differences in Changes in Daily Parameters Between the Intervention and Control Groups We analyzed changes in systolic blood pressure, urine output, serum sodium level, and osmolality (representative clinical parameters are shown in Figure 3) using linear MEMs analysis with a random intercept for each patient to account for within‐subject correlation. Time was modeled as a continuous variable using a natural cubic spline with 3 degrees of freedom to capture nonlinear temporal trajectories. This approach enables the simultaneous assessment of the overall intervention effects and intervention‐by‐time interactions within a single model. The overall intervention‐by‐time interaction (Intervention × Time [overall]) represented the difference in temporal trajectories between the intervention and control groups. The models were also adjusted for potential confounding factors, including age, sex (male vs. female), and the SOFA score at ICU admission, which allowed us to estimate intervention effects independently of these covariates. The temporal trajectories of urine output, serum sodium levels, and osmolality differed significantly between the intervention and control groups, whereas systolic blood pressure did not differ significantly (Table 4). In addition, at multiple time points, serum sodium levels, osmolality, and urine output were higher in the intervention group than in the control group (Figure 3A–D and Table S1). Taken together, these findings suggest that patients in the intervention group tended to exhibit higher serum sodium and osmolality levels as well as increased urine output over time. TABLE 4Differences in changes in daily parameters between the intervention and control groups.VariableEstimateSE p Systolic blood pressure (mmHg)Intervention main effect (vs. Control)2.926.420.65Intervention × Time (overall)——0.30Age0.30.190.12Male sex−2.315.980.70SOFA score−0.490.680.48Urine output (mL/day)Intervention main effect (vs. Control)4.222810.99Intervention × Time (overall)——0.002**Age0.308.870.97Male sex85.92820.76SOFA score43.332.70.19Serum sodium level (mEq/L)Intervention main effect (vs. Control)5.551.480.0004**Intervention × Time (overall)——0.046*Age0.070.050.13Male sex−1.311.510.39SOFA score0.200.170.26Osmolality from baseline (mOsm/kg)Intervention main effect (vs. Control)12.94.800.009**Intervention × Time (overall)——0.007**Age0.070.150.64Male sex−2.314.910.64SOFA score0.940.560.10 Note: Mixed‐effects model analysis was performed on representative daily parameters. Time was modeled using a natural cubic spline with three degrees of freedom. The overall intervention‐by‐time interaction was assessed using a joint Wald test for all interaction terms. A random intercept was used for each patient. *p < 0.05, **p < 0.01, comparing the intervention and control groups.Abbreviations: SE, standard error; SOFA, sequential organ failure assessment. Differences in changes in daily parameters between the intervention and control groups. Note: Mixed‐effects model analysis was performed on representative daily parameters. Time was modeled using a natural cubic spline with three degrees of freedom. The overall intervention‐by‐time interaction was assessed using a joint Wald test for all interaction terms. A random intercept was used for each patient. *p < 0.05, **p < 0.01, comparing the intervention and control groups. Abbreviations: SE, standard error; SOFA, sequential organ failure assessment. Discussion This secondary analysis of patients requiring long‐term CRRT demonstrated that the addition of cIVNa may provide clinical benefits in both survival and kidney outcomes. Although the daily change in systolic blood pressure was statistically similar between the two groups in the MEMs analysis, patients receiving cIVNa experienced significantly fewer hypotensive episodes requiring intervention than those not receiving cIVNa. Improved hemodynamic stability may help preserve kidney perfusion, reduce recurrent ischemic insults, and facilitate kidney recovery. The observed increases in urine output and improvements in fluid balance in the intervention group further support this mechanism. In contrast, the present study confirmed that outcomes with conventional management for long‐term CRRT were extremely poor. Mortality rates were high, discharge rates from the ICU and hospital were low, and successful liberation from RRT was uncommon. These findings align with those of a previous study describing multiorgan dysfunction and mortality among patients undergoing long‐term continuous hemodiafiltration (CHDF) [18]. The Japanese single‐center study reported that 38.9% (14 of 36) of patients required long‐term CHDF for 7 days or longer, and the survival rate more than 7 days after CHDF withdrawal in this group was lower than that in patients requiring short‐term CHDF of 6 days or less (35.7% vs. 72.7%; p‐values not reported). In the long‐term group, only 21.4% (3 of 14) of patients survived for 1 month after CHDF withdrawal. The more favorable osmotic profile observed in the cIVNa group—characterized by higher serum sodium, osmolality, and tonicity—may have contributed to more effective plasma refilling and reduced hemodynamic fluctuations. In the present study, sodium dosing for cIVNa was adjusted with consideration of the substantial negative sodium balance that typically develops during CRRT (Figure 4). Under normal kidney function, urinary sodium excretion generally averages approximately 70 mEq/L when diuretics are administered. In states of intravascular dehydration—such as in sepsis or following major surgery—urinary sodium excretion is further reduced due to kidney autoregulatory mechanisms. However, mechanical fluid removal by ultrafiltration continuously extracts fluid with a sodium concentration of approximately 140 mEq/L. Ali et al. reported that, following diuretic administration, urinary sodium concentration averaged 60 ± 47 mEq/L, compared with 134 ± 8.0 mEq/L in the ultrafiltrate [19]. Similarly, Chung et al. observed in patients with acute decompensated heart failure that urinary sodium concentration in the conventional diuretic group was 85 ± 73 mEq/L, whereas the ultrafiltrate sodium concentration averaged 138 ± 6 mEq/L [20]. Moreover, during the early stages of tubular recovery in AKI, sodium reabsorption by kidney tubules is often inadequate, leading to excessive urinary sodium excretion approaching 140 mEq/L. In this study, sodium supplementation was regulated to mimic kidney autoregulation and compensate for the considerable sodium losses induced by CRRT. Long‐term sodium loss during conventional CRRT can destabilize hemodynamics and potentially worsen prognosis. In the intervention group, cIVNa was administered to regulate sodium excretion in a manner resembling normal kidney responses to diuretics. The removal of 2.0 L of ultrafiltration fluid results in an estimated sodium loss of approximately 280 mEq per day. By administering cIVNa at approximately 5 mEq/h (equivalent to 120 mEq/day) alongside 2.0 L of ultrafiltration, total sodium loss was limited to about 160 mEq/day—comparable to urinary sodium excretion in 2.0 L of urine under diuretic use (urinary sodium concentration ≈70 mEq/L × 2.0 L = 140 mEq). Using this calculation as a reference, sodium dosing in cIVNa was further adjusted based on intravascular volume status: increased during hypovolemia and reduced following hemodynamic stabilization. This sodium adjustment, guided by systemic circulatory assessment, may enhance hemodynamic stability, promote urine output, and improve overall prognosis. Additionally, sodium dosing in cIVNa was individualized according to each patient's serum sodium concentration. In patients with hypernatremia, serum sodium levels decrease rapidly toward the dialysate sodium concentration (approximately 140 mEq/L) due to diffusion during dialysis; consequently, RRT removes larger amounts of sodium in these patients than in those with hyponatremia. To compensate for this substantial sodium loss, the cIVNa sodium dose was increased in patients with hypernatremia. Conversely, in patients with hyponatremia, the cIVNa sodium dose was reduced, accounting for the sodium already supplied by the dialysate or replacement fluid containing approximately 140 mEq/L of sodium. Sodium input–output balance during CRRT management. When kidney function is normal, urinary sodium excretion is typically approximately 70 mEq/L during diuretic therapy. In conditions of intravascular dehydration, such as sepsis or postoperative states, urinary sodium excretion is further reduced by kidney autoregulation. In contrast, ultrafiltration during CRRT continuously removes fluid with a sodium concentration of roughly 140 mEq/L. During the early stages of tubular recovery in acute kidney injury, tubular sodium reabsorption remains impaired, often resulting in excessive urinary sodium excretion approaching 140 mEq/L. Consequently, prolonged sodium loss during conventional CRRT can destabilize hemodynamics and worsen prognosis. In the intervention group, cIVNa was used to regulate sodium balance, simulating the kidney's normal compensatory response to diuretic‐induced natriuresis. In the present study, patients in the intervention group exhibited significantly higher serum sodium levels than those in the control group. In our previous analysis of 92 patients, serum sodium levels at treatment initiation did not differ between the two groups. Among these 92 patients, 22 presented with hypernatremia (serum sodium ≥ 150 mEq/L) at the start of treatment—12 in the control group (CRRT only) and 10 in the intervention group (CRRT with cIVNa). Of the 12 patients with hypernatremia in the control group, six died within 6 days, whereas only one of the 10 hypernatremic patients in the intervention group died during the same period. In the intervention group, both hypernatremia and elevated osmolality/tonicity were gradually corrected through cIVNa, which likely exerted beneficial effects on hemodynamic stability and fluid management. This, in turn, may have contributed to a higher number of hypernatremic patients surviving beyond 7 days. The selective inclusion of patients who underwent CRRT for more than 7 days may have influenced the observed differences in baseline characteristics between groups in the current study. Further research is warranted to clarify the effects of cIVNa in patients presenting with hypernatremia. Interestingly, blood urea nitrogen—a key osmotic solute—was higher in the intervention group than in the control group. The observed increase in blood urea nitrogen was unexpected. Several factors may have contributed to this finding, including the efficiency of blood purification, nutritional supplementation, the catabolic state of the patient, and interruption of CRRT. cIVNa may also influence protein catabolism and blood urea nitrogen dynamics. However, because these factors were not systematically evaluated in this study, their precise mechanisms remain unclear, and further investigation is warranted. Although gradual decreases in osmolarity may help stabilize hemodynamics and renal blood flow, hypernatremia or hyperosmolar states can lead to excessive plasma refilling, hypertension, and adverse neurological effects. Although no statistically significant differences were observed, this study found a higher incidence of hypernatremia and hypertension requiring antihypertensive therapy in the intervention group, which is a major concern. In our ICU, nephrologists closely monitor patients and actively manage their treatment to gradually correct hyperosmolarity, maintain serum sodium concentrations at approximately 145 mEq/L, and appropriately adjust fluid removal to balance plasma refilling. However, during the recovery phase of renal tubular function, rapid increases in serum sodium levels occur, and the management of hypernatremia, particularly after CRRT withdrawal, proves challenging. Furthermore, we believe that plasma refilling during the inflammatory recovery phase, when it overlaps with the hemodynamic stabilizing effects of cIVNa, contributes to the development of hypertension. Neurological complications were not evaluated in this study; nevertheless, careful management is essential. Close attention must be paid to these issues when cIVNa or high‐sodium dialysates are used. Our method should be applied under the careful supervision of dialysis specialists experienced in the use of high‐sodium dialysates, with diligent monitoring and adjustment of therapy while carefully weighing the associated risks and benefits. This study has several limitations. First, it was a secondary analysis of a small‐scale retrospective investigation conducted at a single center. The relatively limited sample size reduced the statistical power to detect differences in some outcomes. The intervention group included a higher proportion of patients who underwent cardiopulmonary bypass surgery, emergency surgery, and presented with hypernatremia; the inability to control for these baseline differences may have influenced the results. Moreover, the criteria for discontinuing CRRT or RRT were not standardized and were determined at the discretion of the attending clinician, which could have introduced additional variability. Second, most patients in the control group were treated before 2018, whereas all patients in the intervention group were treated after 2019. The retrospective design and use of a historical control group introduce the potential for unmeasured confounders. Differences in patient management due to advances in critical care—such as nutrition, nursing practices, rehabilitation, early mobilization, diagnostics, surgical techniques, hemodynamic monitoring, mechanical support devices, and their respective management—could not be entirely excluded. Hemodynamic stabilization achieved through cIVNa may also have facilitated more aggressive nutritional and rehabilitative interventions, representing a secondary effect of improved circulatory stability. Third, to isolate the effects of sodium supplementation via cIVNa, patients requiring specialized treatments, including immunosuppressive therapy, chemotherapy, or organ transplantation, were excluded. However, cIVNa may also provide clinical benefits in these patient populations, warranting further investigation. Fourth, recent studies have highlighted the utility of IHD and SLED using a multimodal approach (MMA) that incorporates high‐sodium, low‐temperature, and bicarbonate‐buffered dialysates in critically ill patients [1, 9, 10, 11, 12, 21]. The use of high‐sodium, low‐temperature, and bicarbonate dialysates during IHD is already recommended in French guidelines [15]. The present study could not determine whether “IHD or SLED with MMA” or “CRRT with cIVNa” offers superior outcomes. Each modality—CRRT, IHD, and SLED—has distinct advantages and limitations [14], and their clinical indications may differ. Further comparative studies are required to clarify these relationships. Conclusion In critically ill patients requiring long‐term CRRT, the addition of cIVNa was associated with improved hemodynamic stability and survival, increased urine output, a more favorable fluid balance, and higher rates of CRRT and RRT withdrawal. These findings suggest that physiologically guided sodium supplementation may promote kidney recovery and enhance survival among patients receiving long‐term CRRT. However, the results of this observational study may have been confounded by the evolution of various treatments. Further prospective studies are warranted to confirm these results, determine optimal sodium dosing strategies, and establish standardized protocols for sodium‐assisted hemodynamic support during CRRT. Funding The authors have nothing to report. Ethics Statement This study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Medical Ethics Committee of Shinshu University School of Medicine (Approval No. 5769). Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Figure S1: Schematic diagram of combination therapy with continuous renal replacement therapy and continuous intravenous sodium infusion. Table S1: Changes in blood pressure, fluid management, and osmolality‐related parameters.